| Miss Candice Theodora Joseph, MD | |
|
356 E Midway Rd, Fort Pierce, FL 34982-7148 | |
| (772) 464-9746 | |
| (772) 474-9750 |
| Full Name | Miss Candice Theodora Joseph |
|---|---|
| Gender | Female |
| Speciality | Infectious Disease |
| Experience | 14 Years |
| Location | 356 E Midway Rd, Fort Pierce, Florida |
| Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1700232667 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207RI0200X | Internal Medicine - Infectious Disease | M150117 (Florida) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Lawnwood Regional Medical Center & Heart Institute | Fort pierce, FL | Hospital |
| Cleveland Clinic Martin North Hospital | Stuart, FL | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Associates In Infectious Diseases | 4486689957 | 7 |
| Midway Specialty Care Center Inc | 9638306087 | 21 |
News Archive
Roche, PTC Therapeutics, Inc. and the SMA Foundation, announced today a licensing agreement for PTC's Spinal Muscular Atrophy (SMA) programme.
Targacept, Inc. today announced top-line results from a Phase 2 trial of TC-5619 as a treatment for inattentive-predominant attention deficit/hyperactivity disorder (ADHDi). In the trial, TC-5619 did not meet the primary outcome measure, change from baseline on the inattention subscale of the Conners' Adult ADHD Rating Scale-Investigator-Rated (CAARS-INV), after four weeks of treatment versus placebo.
In addition to facing new concerns about their health, individuals who are diagnosed with cancer often worry about the financial burdens of treatment.
Young patients with an aggressive form of leukemia who are likely to relapse after chemotherapy treatment can significantly reduce those odds by receiving additional courses of chemotherapy, suggest the findings of a clinical trial led by investigators at Dana-Farber/Children's Hospital Cancer Center in Boston.
› Verified 2 days ago
| Entity Name | Associates In Infectious Diseases |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1336156934 PECOS PAC ID: 4486689957 Enrollment ID: O20051004000220 |
News Archive
Roche, PTC Therapeutics, Inc. and the SMA Foundation, announced today a licensing agreement for PTC's Spinal Muscular Atrophy (SMA) programme.
Targacept, Inc. today announced top-line results from a Phase 2 trial of TC-5619 as a treatment for inattentive-predominant attention deficit/hyperactivity disorder (ADHDi). In the trial, TC-5619 did not meet the primary outcome measure, change from baseline on the inattention subscale of the Conners' Adult ADHD Rating Scale-Investigator-Rated (CAARS-INV), after four weeks of treatment versus placebo.
In addition to facing new concerns about their health, individuals who are diagnosed with cancer often worry about the financial burdens of treatment.
Young patients with an aggressive form of leukemia who are likely to relapse after chemotherapy treatment can significantly reduce those odds by receiving additional courses of chemotherapy, suggest the findings of a clinical trial led by investigators at Dana-Farber/Children's Hospital Cancer Center in Boston.
› Verified 2 days ago
| Entity Name | Midway Specialty Care Center Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1376970814 PECOS PAC ID: 9638306087 Enrollment ID: O20131211000645 |
News Archive
Roche, PTC Therapeutics, Inc. and the SMA Foundation, announced today a licensing agreement for PTC's Spinal Muscular Atrophy (SMA) programme.
Targacept, Inc. today announced top-line results from a Phase 2 trial of TC-5619 as a treatment for inattentive-predominant attention deficit/hyperactivity disorder (ADHDi). In the trial, TC-5619 did not meet the primary outcome measure, change from baseline on the inattention subscale of the Conners' Adult ADHD Rating Scale-Investigator-Rated (CAARS-INV), after four weeks of treatment versus placebo.
In addition to facing new concerns about their health, individuals who are diagnosed with cancer often worry about the financial burdens of treatment.
Young patients with an aggressive form of leukemia who are likely to relapse after chemotherapy treatment can significantly reduce those odds by receiving additional courses of chemotherapy, suggest the findings of a clinical trial led by investigators at Dana-Farber/Children's Hospital Cancer Center in Boston.
› Verified 2 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Miss Candice Theodora Joseph, MD 356 E Midway Rd, Fort Pierce, FL 34982-7148 Ph: (772) 464-9746 | Miss Candice Theodora Joseph, MD 356 E Midway Rd, Fort Pierce, FL 34982-7148 Ph: (772) 464-9746 |
News Archive
Roche, PTC Therapeutics, Inc. and the SMA Foundation, announced today a licensing agreement for PTC's Spinal Muscular Atrophy (SMA) programme.
Targacept, Inc. today announced top-line results from a Phase 2 trial of TC-5619 as a treatment for inattentive-predominant attention deficit/hyperactivity disorder (ADHDi). In the trial, TC-5619 did not meet the primary outcome measure, change from baseline on the inattention subscale of the Conners' Adult ADHD Rating Scale-Investigator-Rated (CAARS-INV), after four weeks of treatment versus placebo.
In addition to facing new concerns about their health, individuals who are diagnosed with cancer often worry about the financial burdens of treatment.
Young patients with an aggressive form of leukemia who are likely to relapse after chemotherapy treatment can significantly reduce those odds by receiving additional courses of chemotherapy, suggest the findings of a clinical trial led by investigators at Dana-Farber/Children's Hospital Cancer Center in Boston.
› Verified 2 days ago
Sabrina Marie Seus, D.O. Infectious Disease Medicare: Accepting Medicare Assignments Practice Location: 1700 South 23rd Street, Lawnwood Regional Medical Center, Fort Pierce, FL 34950 Phone: 772-467-8291 | |
Ms. Kirsten Alexandra Nathan, Infectious Disease Medicare: Accepting Medicare Assignments Practice Location: 1700 S 23rd St, Fort Pierce, FL 34950 Phone: 772-461-4000 | |
Dr. Perry R Lloyd Iii, MD Infectious Disease Medicare: Accepting Medicare Assignments Practice Location: 2207 Sunrise Blvd, Fort Pierce, FL 34950 Phone: 772-465-0491 Fax: 772-461-6360 | |
Mrs. Marcy Ann Studzinski, DO Infectious Disease Medicare: Medicare Enrolled Practice Location: 1900 Nebraska Avenue, Suite 9, Fort Pierce, FL 34950 Phone: 772-465-4499 Fax: 772-466-0832 | |
Mohammad Izhar, M.D. Infectious Disease Medicare: Accepting Medicare Assignments Practice Location: 2000 Hartman Rd Ste 1, Fort Pierce, FL 34947 Phone: 724-651-1707 Fax: 772-465-1171 | |
Mr. Kamalakar T Rao, MD Infectious Disease Medicare: Accepting Medicare Assignments Practice Location: 1900 Nebraska Avenue, Suite 9, Fort Pierce, FL 34950 Phone: 772-465-4499 Fax: 772-466-0832 | |
Dr. Samerah G Razuman, M.D. Infectious Disease Medicare: Accepting Medicare Assignments Practice Location: 2000 Hartman Rd Ste 1, Fort Pierce, FL 34947 Phone: 772-465-1170 Fax: 772-465-1171 |